Rowshani Ajda T, Bemelman Frederike J, van Leeuwen Ester M M, van Lier René A W, ten Berge Ineke J M
Department of Internal Medicine, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, 1100 DE Amsterdam, the Netherlands.
Transplantation. 2005 Feb 27;79(4):381-6. doi: 10.1097/01.tp.0000148239.00384.f0.
Primary cytomegalovirus (CMV) infection is a major cause of morbidity and mortality in recipients after solid organ transplantation (SOT). Widespread and prolonged use of antiviral drugs has changed the natural course of CMV disease by delaying its onset and causing drug resistance. CMV induces a strong cellular immune response, even in immunosuppressed patients, and has developed strategies to evade this immune surveillance. This review summarizes challenges in managing CMV infection in transplant recipients and highlights current insights in the cellular immune response against CMV.
原发性巨细胞病毒（CMV）感染是实体器官移植（SOT）受者发病和死亡的主要原因。抗病毒药物的广泛和长期使用通过延迟其发病和导致耐药性改变了CMV疾病的自然病程。CMV即使在免疫抑制患者中也能诱导强烈的细胞免疫反应，并且已经形成了逃避这种免疫监视的策略。本综述总结了移植受者CMV感染管理中的挑战，并强调了目前对针对CMV的细胞免疫反应的见解。
